NCT01521585已完成2 期
A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196
Siena Biotech S.p.A.1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Safety and tolerability
研究概览
简要总结
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Genetically confirmed, manifest HD (CAG repeat length ≥ 36) and motor signs of HD (including motor score of the UHDRS ≥ 5).
- •Clinical Stages I to III (Total Functional Capacity Subscale Score [TFC] of ≥ 3).
- •Patients must be anticipated to be ambulatory and able to attend outpatient visits for the duration of the study.
- •Patients must be aged ≥ 30 years and ≤ 70 years.
- •Body mass index between 18 and 31 kg/m2 inclusive, and a body weight greater than 50 kg.
- •Patients must be able to give informed consent or have a legal representative who can consent on their behalf. Patients must be able to comply with trial procedures.
- •Patients must have no clinically significant and relevant medical or psychiatric history that could affect the conduct of the study and evaluation of the data, as ascertained by the Investigator through detailed medical history and screening assessments.
- •Male patients must agree to use condoms during the entire duration of the study and for 3 months following the last dose of study drug.
- •Females of childbearing potential (last menses less than 1 year prior to enrolment).
排除标准
- •Participation in a study with an investigational drug within 30 days of the Baseline Visit.
- •Any prior or concomitant use of Class I or Class II histone deacetylase (HDAC) inhibitors such as Zolinza®/vorinostat or belinostat.
- •Clinical evidence of significant or unstable medical illness in the Investigator's judgement, including screening transaminases (AST or ALT) ≥ 3 times the upper limit of normal (ULN), or an estimated GFR < 60 mL/min, or unexplained proteinuria or microscopic haematuria in an uncontaminated sample obtained at Screening and confirmed on repeat testing.
- •QTcF interval >450 ms in men and >470 ms in women or PR >220 ms, or other clinically relevant abnormal ECG findings
- •Women who are pregnant or breastfeeding.
- •Clinically significant abnormalities in the screening laboratory studies which, in the opinion of the Investigator, would interfere with participation in the study.
- •Current evidence or history (within 1 year of baseline) of psychosis, hallucinations or delusions, including major depression with psychotic features, as defined in the DSM-IV-TR. Patients currently experiencing mild depression, or moderate depression which is adequately and appropriately treated in the judgment of the Investigator, can participate if depression is not expected to interfere with study participation.
- •Suicide risk, as determined by meeting any of the following criteria:
- •A suicide attempt within the past year or suicidal ideation within 60 days of the Baseline Visit (Day 1).
- •Significant risk of suicide, as judged by the Principal Investigator, based on the psychiatric interview or information collected in the C-SSRS.
- •Current diagnosis or history (within 1 year of baseline) of any alcohol or substance abuse (except nicotine and caffeine-related disorders) as defined in the DSM-IV-TR.
- •Known allergy to any ingredient in the study drug (active and/or placebo).
- •A history of malignancy of any type within 2 years prior to screening. A history of surgically excised non-melanoma skin cancers is permitted.
- •Any relevant condition, behaviour, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the patient unsuitable for entry into the study.
研究组 & 干预措施
SEN0014196 50 mg oral tablet
Experimental
干预措施: SEN0014196 (Drug)
SEN0014196 200 mg oral tablet
Experimental
干预措施: SEN0014196 (Drug)
Placebo tablet
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: 12 weeks
Adverse event (AE) reporting, 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and laboratory safety tests. Suicide risk (Columbia Suicide Severity Rating Scale,C-SSRS).
次要结局
- Modulation of candidate pharmacodynamic markers(12 weeks)
- Pharmacokinetic profile(12 weeks)
- Short-term clinical effects(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of TG103 in Chinese Healthy Adult SubjectsHealthyNCT03990090CSPC ZhongQi Pharmaceutical Technology Co., Ltd.32
已完成
1 期
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseParkinson's DiseaseNCT00866502Newron Sweden AB12
已完成
1 期
Single Ascending Dose Study of AMG 570 in Healthy SubjectsSystemic Lupus ErythematosusNCT02618967Amgen56
Unknown
1 期
Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult SubjectsHealthyNCT02622230Xinjiang Uygur Pharmaceutical Co., Ltd.60
已完成
1 期
Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy VolunteersHealthy VolunteersNCT02603224miRagen Therapeutics, Inc.54